https://www.selleckchem.com/products/tas4464.html
The median follow-up was 36 months (IQR, 1-156 months). Predictors of decreased survival were age 74, larger tumors, and N1 or M1 disease. Median survival across the entire cohort was 58 months. Median survival was 92 months, 88 months, 44 months, and 26 months for primary tumors ≤2.5 cm, 2.6-3.5 cm, 3.5-5.0 cm, and 5.0 cm, respectively (P less then .0001). Conclusions SABR is being increasingly used for renal cell carcinoma across the United States with excellent outcomes in smaller tumors. © 2019 The Author(s).Purpose To revie
Мне нравится
Комментарий
Перепост
